Boston Scientific Co. (NYSE:BSX) Shares Acquired by Empowered Funds LLC

Empowered Funds LLC raised its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 13.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,615 shares of the medical equipment provider's stock after purchasing an additional 3,202 shares during the quarter. Empowered Funds LLC's holdings in Boston Scientific were worth $2,377,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB increased its stake in Boston Scientific by 21.9% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 17,087 shares of the medical equipment provider's stock valued at $1,526,000 after purchasing an additional 3,069 shares during the period. Kingsview Wealth Management LLC increased its stake in Boston Scientific by 9.9% in the fourth quarter. Kingsview Wealth Management LLC now owns 6,563 shares of the medical equipment provider's stock valued at $586,000 after purchasing an additional 593 shares during the period. Apollon Wealth Management LLC increased its stake in Boston Scientific by 9.7% in the fourth quarter. Apollon Wealth Management LLC now owns 20,355 shares of the medical equipment provider's stock valued at $1,818,000 after purchasing an additional 1,793 shares during the period. Shepherd Financial Partners LLC boosted its holdings in shares of Boston Scientific by 1.1% in the fourth quarter. Shepherd Financial Partners LLC now owns 22,724 shares of the medical equipment provider's stock valued at $2,030,000 after acquiring an additional 250 shares in the last quarter. Finally, Barrett & Company Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $379,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 6,389 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.06, for a total value of $671,228.34. Following the transaction, the executive vice president now owns 24,293 shares of the company's stock, valued at approximately $2,552,222.58. This trade represents a 20.82 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 87,326 shares of company stock valued at $8,673,948 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.9 %

Shares of BSX traded down $0.98 on Tuesday, hitting $105.13. 2,346,733 shares of the stock traded hands, compared to its average volume of 5,965,439. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $154.95 billion, a P/E ratio of 84.11, a P/E/G ratio of 2.79 and a beta of 0.80. The stock's 50 day moving average is $96.79 and its two-hundred day moving average is $88.61. Boston Scientific Co. has a 1 year low of $65.33 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, January 29th. Mizuho boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Thursday, February 6th. Finally, Royal Bank of Canada upped their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.